Echosens, A High-Technology Company Offering Liver Diagnostic Solutions, And Novo Nordisk A/S, A Leading Global Healthcare Company, Today Announced A Partnership To Advance Early Diagnosis Of Non-Alcoholic Steatohepatitis (Nash) And Increase Awareness Of The Disease Among Patients, Healthcare Providers And Other Stakeholders.Nash Is A Chronic Metabolic Liver Disease That Affects More Than 115 Million People Worldwide1. The Condition Is Caused By Build-Up Of Fat And Inflammation In The Liver. This Causes Progressive Damage To The Liver And Can Lead To End-Stage Liver Disease And Death.Nash Is A
